Wei Shulin, Wang Li, Evans Paul C, Xu Suowen
School of Life Sciences, Jilin University, Changchun, China; Department of Endocrinology, Institute of Endocrine and Metabolic Disease, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei, China.
Department of Biomedical Sciences, City University of Hong Kong, China.
Drug Discov Today. 2024 Mar;29(3):103910. doi: 10.1016/j.drudis.2024.103910. Epub 2024 Feb 1.
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a significant threat to human health and cause a tremendous socioeconomic burden. Currently, the molecular mechanisms of NAFLD and NASH remain incompletely understood, and no effective pharmacotherapies have been approved. In the past five years, significant advances have been achieved in our understanding of the pathomechanisms and potential pharmacotherapies of NAFLD and NASH. Research advances include the investigation of the effects of the fibroblast growth factor 21 (FGF21) analog pegozafermin and the thyroid hormone receptor-β (THRβ) agonist resmetriom on hepatic fat content, NASH resolution and/or fibrosis regression. Future directions of NAFLD and NASH research (including combination therapy, organoids and humanized mouse models) are also discussed in this state-of-the-art review.
非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）对人类健康构成重大威胁，并造成巨大的社会经济负担。目前，NAFLD和NASH的分子机制仍未完全明确，且尚无获批的有效药物疗法。在过去五年中，我们对NAFLD和NASH的发病机制及潜在药物疗法的理解取得了重大进展。研究进展包括对成纤维细胞生长因子21（FGF21）类似物佩戈泽费明和甲状腺激素受体-β（THRβ）激动剂瑞美替昂对肝脏脂肪含量、NASH缓解和/或纤维化消退影响的研究。本前沿综述还讨论了NAFLD和NASH研究的未来方向（包括联合治疗、类器官和人源化小鼠模型）。
